Alfuzosin

From Wikipedia, the free encyclopedia - View original article

Alfuzosin
Alfuzosin.svg
Alfuzosin ball-and-stick.png
Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Clinical data
Trade namesUroxatral
AHFS/Drugs.commonograph
MedlinePlusa604002
Pregnancy cat.B2 (AU) B (US)
Legal statusPOM (UK) -only (US)
RoutesOral
Pharmacokinetic data
Bioavailability49%
Protein binding82%-90%
MetabolismHepatic (CYP3A4-mediated)
Half-life10 hours
ExcretionFecal (69%) and renal (24%)
Identifiers
CAS number81403-80-7 YesY
ATC codeG04CA01
PubChemCID 2092
DrugBankDB00346
ChemSpider2008 YesY
UNII90347YTW5F YesY
KEGGD07124 YesY
ChEBICHEBI:51141 YesY
ChEMBLCHEMBL709 YesY
Chemical data
FormulaC19H27N5O4 
Mol. mass389.449 g/mol
 YesY (what is this?)  (verify)
 
Jump to: navigation, search
Alfuzosin
Alfuzosin.svg
Alfuzosin ball-and-stick.png
Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Clinical data
Trade namesUroxatral
AHFS/Drugs.commonograph
MedlinePlusa604002
Pregnancy cat.B2 (AU) B (US)
Legal statusPOM (UK) -only (US)
RoutesOral
Pharmacokinetic data
Bioavailability49%
Protein binding82%-90%
MetabolismHepatic (CYP3A4-mediated)
Half-life10 hours
ExcretionFecal (69%) and renal (24%)
Identifiers
CAS number81403-80-7 YesY
ATC codeG04CA01
PubChemCID 2092
DrugBankDB00346
ChemSpider2008 YesY
UNII90347YTW5F YesY
KEGGD07124 YesY
ChEBICHEBI:51141 YesY
ChEMBLCHEMBL709 YesY
Chemical data
FormulaC19H27N5O4 
Mol. mass389.449 g/mol
 YesY (what is this?)  (verify)

Alfuzosin (INN, provided as the hydrochloride salt) is an α1 receptor antagonist used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xatral, and in Egypt under name of Prostetrol. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

Side effects[edit]

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

Contraindications[edit]

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.

External links[edit]